| Assessment Status | Assessment process complete |
| HTA ID | 19029 |
| Drug | Tildrakizumab |
| Brand | Ilumetri® |
| Indication | For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 30/07/2019 |
| Rapid review completed | 28/08/2019 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tildrakizumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
| Full pharmacoeconomic assessment commissioned by HSE | 19/05/2020 |
| Pre-submission consultation with Applicant | 08/02/2021 |
| Full submission received from Applicant | 04/05/2021 |
| Preliminary review sent to Applicant | 20/07/2021 |
| NCPE assessment re-commenced | 23/08/2021 |
| Factual accuracy sent to Applicant | 15/10/2021 |
| NCPE assessment re-commenced | 03/11/2021 |
| NCPE assessment completed | 25/11/2021 |
| NCPE assessment outcome | The NCPE recommends that tildrakizumab (Ilumetri®), for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy and who have failed treatment with non-biologic therapies and first-line biologic treatment with adalimumab, be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations May 2022.
